Lightwave Logic (LWLG) 10-K 24 Mar 15 2014 FY Annual report Financial data

Document_and_Entity_Informatio

Document and Entity Information (USD $)	12 Months Ended
	Dec. 31, 2014	Mar. 23, 2015	Jun. 30, 2014
Document and Entity Information [Abstract]
Entity Registrant Name	Lightwave Logic, Inc.
Entity Central Index Key	1325964
Document Type	10-K
Document Period End Date	31-Dec-14
Amendment Flag	FALSE
Current Fiscal Year End Date	-19
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Filer Category	Smaller Reporting Company
Entity Public Float			$41,479,075
Entity Common Stock, Shares Outstanding		58,405,704
Document Fiscal Period Focus	FY
Document Fiscal Year Focus	2014

BALANCE_SHEETS

BALANCE SHEETS (USD $)	Dec. 31, 2014	Dec. 31, 2013
CURRENT ASSETS
Cash and cash equivalents	$3,165,940	$2,270,704
Prepaid expenses and other current assets	128,227	132,204
Total Current Assets	3,294,167	2,402,908
PROPERTY AND EQUIPMENT - NET	375,227	298,360
OTHER ASSETS
Intangible assets - net	610,029	543,540
TOTAL ASSETS	4,279,423	3,244,808
CURRENT LIABILITIES
Accounts payable	178,165	65,410
Accounts payable and accrued expenses- related parties	10,323	48,817
Accrued expenses	33,353	7,949
TOTAL LIABILITIES	221,841	122,176
STOCKHOLDERS' EQUITY
Preferred stock, $0.001 par value, 1,000,000 authorized, no shares issued or outstanding
Common stock $0.001 par value, 100,000,000 authorized, 58,381,854 and 52,617,789 issued and outstanding at December 31, 2014 and December 31, 2013	58,382	52,618
Additional paid-in-capital	40,753,189	35,414,206
Accumulated deficit	-36,753,989	-32,344,192
TOTAL STOCKHOLDERS' EQUITY	4,057,582	3,122,632
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY	$4,279,423	$3,244,808

BALANCE_SHEETS_Parenthetical

BALANCE SHEETS (Parenthetical) (USD $)	Dec. 31, 2014	Dec. 31, 2013
BALANCE SHEETS [Abstract]
Preferred stock, par value	$0.00	$0.00
Preferred stock, shares authorized	1,000,000	1,000,000
Preferred stock, shares issued
Preferred stock, shares outstanding
Common stock, par value	$0.00	$0.00
Common stock, shares authorized	100,000,000	100,000,000
Common stock, shares issued	58,381,854	52,617,789
Common stock, shares outstanding	58,381,854	52,617,789

STATEMENTS_OF_OPERATIONS

STATEMENTS OF OPERATIONS (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
STATEMENTS OF OPERATIONS [Abstract]
NET SALES	$2,500
COST AND EXPENSE
Research and development	2,849,620	2,068,050
General and administrative	1,546,064	1,632,387
TOTAL COST AND EXPENSE	4,395,684	3,700,437
LOSS FROM OPERATIONS	-4,393,184	-3,700,437
OTHER INCOME (EXPENSE)
Interest income	249	267
Commitment fee and interest expense	-16,862	-212,156
NET LOSS	($4,409,797)	($3,912,326)
Basic and Diluted Loss per Share	($0.08)	($0.08)
Basic and Diluted Weighted Average Number of Shares	55,637,906	51,672,177

STATEMENT_OF_STOCKHOLDERS_EQUI

STATEMENT OF STOCKHOLDERS' EQUITY (USD $)	Total	Common Stock [Member]	Paid-in Capital [Member]	Accumulated Deficit [Member]
Balance at Dec. 31, 2012	$3,661,046	$50,161	$32,042,751	($28,431,866)
Balance, shares at Dec. 31, 2012		50,160,758
Common stock issued to institutional investors	2,278,500	2,128	2,276,372
Common stock issued to institutional investors, shares		2,128,386
Common stock issued for additional commitment shares	212,156	235	211,921
Common stock issued for additional commitment shares, shares		234,795
Reversal of common stock issuance		-2	2
Reversal of common stock issuance, shares		-2,000
Exercise of options	49,983	63	49,920
Exercise of options, shares		63,350
Exercise of warrants	22,525	33	22,492
Exercise of warrants, shares		32,500
Options issued for services	674,897		674,897
Warrants issued for services	135,851		135,851
Net loss	-3,912,326			-3,912,326
Balance at Dec. 31, 2013	3,122,632	52,618	35,414,206	-32,344,192
Balance, shares at Dec. 31, 2013	52,617,789	52,617,789
Common stock issued to institutional investors	1,036,148	1,065	1,035,083
Common stock issued to institutional investors, shares		1,063,648
Common stock issued for additional commitment shares	16,862	15	16,847
Common stock issued for additional commitment shares, shares		15,630
Common stock issued in private placement	3,140,000	4,207	3,135,793
Common stock issued in private placement, shares		4,207,600
Common stock issued for services	24,500	28	24,472
Common stock issued for services, shares		28,187
Exercise of options	11,000	35	10,965
Exercise of options, shares		35,000
Exercise of warrants	142,830	414	142,416
Exercise of warrants, shares		414,000
Options issued for services	824,726		824,726
Warrants issued for services	148,681		148,681
Net loss	-4,409,797			-4,409,797
Balance at Dec. 31, 2014	$4,057,582	$58,382	$40,753,189	($36,753,989)
Balance, shares at Dec. 31, 2014	58,381,854	58,381,854

STATEMENT_OF_STOCKHOLDERS_EQUI1

STATEMENT OF STOCKHOLDERS' EQUITY (Parenthetical) (Reversal Of Common Stock Issuance [Member], USD $)	12 Months Ended
	Dec. 31, 2013
Reversal Of Common Stock Issuance [Member]
Equity Issuance [Line Items]
Equity issuance, amount per share	$0.50

STATEMENTS_OF_CASH_FLOWS

STATEMENTS OF CASH FLOWS (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
CASH FLOWS FROM OPERATING ACTIVITIES
Net loss	($4,409,797)	($3,912,326)
Adjustment to reconcile net loss to net cash used in operating activities
Warrants issued for services	148,681	135,851
Stock options issued for services	824,726	674,897
Common stock issued for services and fees	41,362	212,156
Depreciation and amortization of patents	151,183	126,773
(Increase) decrease in assets
Prepaid expenses and other current assets	3,977	-42,229
Increase (decrease) in liabilities
Accounts payable	112,755	-30,974
Accounts payable and accrued expenses-related parties	-38,494	-6,789
Accrued expenses	25,404	4,611
Net cash used in operating activities	-3,140,203	-2,838,030
CASH FLOWS FROM INVESTING ACTIVITIES
Cost of intangibles	-81,350	-69,875
Purchase of equipment, furniture and leasehold improvements	-213,189	-109,278
Net cash used in investing activities	-294,539	-179,153
CASH FLOWS FROM FINANCING ACTIVITIES
Issuance of common stock, private placement	3,140,000
Issuance of common stock, exercise of options and warrants	153,830	72,508
Issuance of common stock, institutional investor	1,036,148	2,278,500
Net cash provided by financing activities	4,329,978	2,351,008
NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS	895,236	-666,175
CASH AND CASH EQUIVALENTS - BEGINNING OF YEAR	2,270,704	2,936,879
CASH AND CASH EQUIVALENTS - END OF YEAR	$3,165,940	$2,270,704

SUMMARY_OF_SIGNIFICANT_ACCOUNT

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	12 Months Ended
	Dec. 31, 2014
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES [Abstract]
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	NOTE 1 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
	History and Nature of Business
	Lightwave Logic, Inc. is a technology Company focused on the development of next generation photonic devices and non-linear optical polymer materials systems for applications in high speed fiber-optic data communications and optical computing markets. Currently the Company is in various stages of photonic device and materials development and evaluation with potential customers and strategic partners. The Company expects the next revenue stream to be in sales of non-linear optical polymers, prototype devices and product development agreements prior to moving into production.
	The Company's current development activities are subject to significant risks and uncertainties, including failing to secure additional funding to operationalize the Company's technology now under development.
	Lightwave Logic, Inc., formerly Third-Order Nanotechnologies, Inc., formerly PSI-Tec Holdings, Inc., formerly Eastern Idaho Internet Service, Inc. (the "Company") was organized under the laws of the State of Nevada in 1997. The Company was engaged in the business of marketing internet services until June 30, 1998, at which time the principal assets of the business were sold and operations were discontinued. The Company was inactive until the acquisition of PSI-TEC Corporation ("PSI-TEC") on July 14, 2004, at which time the name was changed to PSI-TEC Holdings, Inc.
	Merger
	On July 14, 2004, the Company acquired PSI-TEC. Under the terms of the merger agreement, the stockholders of PSI-TEC received 15,600,000 shares of common stock in exchange for its 2,206,280 shares. Following the merger, the Company changed its name to PSI-TEC Holdings, Inc. Under accounting principles generally accepted in the United States, the share exchange is considered to be a capital transaction in substance rather than a business combination. That is, the share exchange is equivalent to the issuance of stock by PSI-TEC Holdings, Inc. for the net monetary assets of PSI-TEC, accompanied by a recapitalization, and is accounted for as a change of capital structure. Accordingly, the accounting for the share exchange was identical to that resulting from a reverse acquisition, except no goodwill was recorded. Under reverse takeover accounting, the post-reverse acquisition comparative historical financial statements of the legal acquirer, PSI-TEC Holdings, Inc., are those of the legal acquiree, PSI-TEC, which is considered to be the accounting acquirer. On October 20, 2006, PSI-TEC Holdings, Inc. and PSI-TEC merged and changed its name to Third-Order Nanotechnologies, Inc. On March 10, 2008, Third-Order Nanotechnologies, Inc. changed its name to Lightwave Logic, Inc.
	Basis of Presentation
	The financial statements are presented in accordance with Financial Accounting Standards Board of Accounting Standards Codification ("FASB ASC") 915 for development stage companies. The accompanying financial statements are presented in accordance with accounting principles generally accepted in the United States of America.
	Estimates
	The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying disclosures. Although these estimates are based on management's best knowledge of current events and actions the Company may undertake in the future, actual results could differ from the estimates.
	Cash Equivalents
	For the purposes of the statement of cash flows, the Company considers all highly liquid instruments with maturities of three months or less at the time of purchase to be cash equivalents.
	Concentration of Credit Risk
	Certain financial instruments potentially subject the Company to concentrations of credit risk. These financial instruments consist primarily of cash. At December 31, 2014, the Company did have deposits with a financial institution that exceed the Federal Depository Insurance coverage.
	Property and Equipment
	Equipment is stated at cost. Depreciation is principally provided by use of straight-line methods for financial and tax reporting purposes over the estimated useful lives of the assets, generally 5 years. When property is retired or otherwise disposed of, the cost and accumulated depreciation are removed from the accounts and any resulting gain or loss is included in operations.
	Intangible Assets
	Definite-lived intangible assets are stated at cost. Patents are amortized over their estimated useful lives, generally 20 years. When certain patent applications are abandoned by the Company for claims that are covered by patents already granted to the Company, the cost of patent applications and accumulated amortization are removed from the accounts and the resulting expense is reflected in the statement of operations.
	Fair Value of Financial Instruments
	The Company's financial instruments consist of cash, accounts payable and accrued expenses. The carrying values of cash, accounts payable and accrued expenses approximate fair value because of their short maturities.
	Income Taxes
	The Company follows FASB ASC 740, "Income Taxes," which requires an asset and liability approach to financial accounting and reporting for income taxes. Deferred income tax assets and liabilities are computed annually for temporary differences between the financial statement and tax bases of assets and liabilities that will result in taxable or deductible amounts in the future based on enacted tax laws and rates applicable to the periods in which the differences are expected to affect taxable income. Valuation allowances are established when necessary to reduce deferred tax assets to the amount expected to be realized. Income tax expense is the tax payable or refundable for the period plus or minus the change during the period in deferred tax assets and liabilities.
	Stock-based Payments
	The Company accounts for stock-based compensation under the provisions of FASB ASC 718, "Compensation - Stock Compensation" which requires the measurement and recognition of compensation expense for all stock-based awards made to employees and directors based on estimated fair values on the grant date. The Company estimates the fair value of stock-based awards on the date of grant using the Black-Scholes model. The value of the portion of the award that is ultimately expected to vest is recognized as expense over the requisite service periods using the straightline method. The Company accounts for stock-based compensation awards to nonemployees in accordance with FASB ASC 505-50, "Equity-Based Payments to Non-Employees (“ASC 505-50”). Under ASC 505-50, the Company determines the fair value of the warrants or stock-based compensation awards granted as either the fair value of the consideration received or the fair value of the equity instruments issued, whichever is more reliably measurable. All issuances of stock options or other equity instruments to non-employees as consideration for goods or services received by the Company are accounted for based on the fair value of the equity instruments issued. Any stock options issued to non-employees are recorded as an expense and additional paid in capital in stockholders' equity over the applicable service periods.
	Loss Per Share
	The Company follows FASB ASC 260, "Earnings per Share", resulting in the presentation of basic and diluted earnings per share. Because the Company reported a net loss in 2014 and 2013, common stock equivalents, including stock options and warrants were anti-dilutive; therefore, the amounts reported for basic and dilutive loss per share were the same.
	Recoverability of Long Lived Assets
	The Company follows FASB ASC 360, "Property, Plant, and Equipment". Long-lived assets to be held and used are reviewed for impairment whenever events or changes in circumstances indicate that the related carrying amount may not be recoverable. When required, impairment losses on assets to be held and used are recognized based on the excess of the asset's carrying amount.
	Comprehensive Income
	The Company follows FASB ASC 220.10, "Reporting Comprehensive Income." Comprehensive income is a more inclusive financial reporting methodology that includes disclosure of certain financial information that historically has not been recognized in the calculation of net income. Since the Company has no items of other comprehensive income, comprehensive income (loss) is equal to net loss.
	Recently Adopted Accounting Pronouncements
	In June 2014, the FASB issued ASU No. 2014-10, "Development Stage Entities (Topic 915), Elimination of Certain Financial Reporting Requirements", including an Amendment to Variable Interest Entities Guidance in Topic 810, "Consolidation". The amendments in this Update remove the definition of a development stage entity from the Master Glossary of the Accounting Standards Codification, thereby removing the financial reporting distinction between development stage entities and other reporting entities from U.S. GAAP. In addition, the amendments eliminate the requirements for development stage entities to (1) present inception-to-date information in the statements of income, cash flows, and shareholder equity, (2) label the financial statements as those of a development stage entity, (3) disclose a description of the development stage activities in which the entity is engaged, and (4) disclose in the first year in which the entity is no longer a development stage entity that in prior years it had been in the development stage.
	The amendments also clarify that the guidance in Topic 275, "Risks and Uncertainties", is applicable to entities that have not commenced planned principal operations.
	The amendments related to the elimination of inception-to-date information and the other remaining disclosure requirements of Topic 915 should be applied retrospectively except for the clarification to Topic 275, which shall be applied prospectively. For public business entities, those amendments are effective for annual reporting periods beginning after December 15, 2014, and interim periods therein.
	For public business entities, the amendment eliminating the exception to the sufficiency-of-equity-at-risk criterion for development stage entities in paragraph 810-10-15-16 should be applied retrospectively for annual reporting periods beginning after December 15, 2015, and interim periods therein.
	Early application of each of the amendments is permitted for any annual reporting period or interim period for which the entity's financial statements have not yet been issued (public business entities) or made available for issuance (other entities). Upon adoption, entities will no longer present or disclose any information required by Topic 915.
	The Company adopted the amendments retrospectively beginning in interim period ending June 30, 2014.
	Recently Issued Accounting Pronouncements Not Yet Adopted
	In August 2014, the FASB issued ASU 2014-15, Presentation of Financial Statements – Going Concern (Subtopic 205-40), Disclosure of Uncertainties about an Entity's Ability to Continue as a Going Concern. The amendments in this Update provide guidance about management's responsibility to evaluate whether there are conditions or events, considered in the aggregate, that raise substantial doubt about the entity's ability to continue as a going concern within one year after the date that the financial statements are issued and to provide related footnote disclosures. Substantial doubt about an entity's ability to continue as a going concern exists when relevant conditions and events, considered in the aggregate, indicate that it is probable that the entity will be unable to meet its obligations as they become due within one year after the date that the financial statements are issued. The amendments in this Update are effective for the annual period ending after December 15, 2016, and for annual periods and interim periods thereafter. Early application is permitted.

MANAGEMENTS_PLANS

MANAGEMENT'S PLANS	12 Months Ended
	Dec. 31, 2014
MANAGEMENT'S PLANS [Abstract]
MANAGEMENT'S PLANS	NOTE 2 – MANAGEMENT'S PLANS
	As a technology company focusing on the development of the next generation photonic devices and non-linear optical polymer materials systems, substantial net losses have been incurred since inception. The Company has satisfied capital requirements since inception primarily through the issuance and sale of its common stock. The Company currently has a cash position of approximately $2,450,000. Based upon the current cash position and expenditures of approximately $295,000 per month and no debt service, management believes the Company has sufficient funds currently to finance its operations through October 2015. In June 2013, the Company signed an agreement with an institutional investor to sell up to $20 million of common stock. Under the agreement subject to certain conditions and at the Company's sole discretion, the institutional investor has committed to invest up to $20 million in the Company's common stock over a 30-month period with the remaining available amount of $18,485,352. The Company filed a registration statement with the U.S. Securities and Exchange Commission covering the resale of the shares that may be issued to the institutional investor. Historically the Company has successfully raised sufficient cash to fund its operations.

PROPERTY_AND_EQUIPMENT

PROPERTY AND EQUIPMENT	12 Months Ended
	Dec. 31, 2014
PROPERTY AND EQUIPMENT [Abstract]
PROPERTY AND EQUIPMENT	NOTE 3 – PROPERTY AND EQUIPMENT
	Property and equipment consists of the following:
		December 31,		December 31,
		2014		2013
	Office equipment	$	51,322	$	24,244
	Lab equipment		544,858		474,049
	Furniture		18,782		4,061
	Leasehold improvements		136,900		37,519
			751,862		539,873
	Less: Accumulated depreciation		376,635		241,513
		$	375,227	$	298,360
	Depreciation expense for the years ending December 31, 2014 and 2013 was $136,322 and $111,912.

INTANGIBLE_ASSETS

INTANGIBLE ASSETS	12 Months Ended
	Dec. 31, 2014
INTANGIBLE ASSETS [Abstract]
INTANGIBLE ASSETS	NOTE 4 – INTANGIBLE ASSETS
	This represents legal fees and patent fees associated with the prosecution of patent applications. The Company has recorded amortization expenses on the Spacer and Chromophore patents granted by the United States Patent and Trademark Office in February 2011, April 2011 and September 2012, which are amortized over their legal life of 20 years and Chromophore patent granted by the Australian Patent Office in November 2012 which is amortized over its legal life of 20 years. Certain patent applications are abandoned by the Company when the claims are covered by patents already granted to the Company. Patent applications abandoned have been written off at full capitalized cost. No amortization expense has been recorded on the remaining patent applications since patents have yet to be granted. Once the patents are granted, the cost of the patents will be amortized over their legal lives, which is generally 20 years.
	Patents consists of the following:
		December 31,		December 31,
		2014		2013
	Patents	$	660,586	$	579,235
	Less: Accumulated amortization		50,557		35,695
		$	610,029	$	543,540
	Amortization expense for the years ending December 31, 2014 and 2013 was $14,861. Expense for abandoned patents for claims covered by patents already granted to the Company are recorded in research and development expenses and for the years ending December 31, 2014 and 2013 were $0.

COMMITMENTS

COMMITMENTS	12 Months Ended
	Dec. 31, 2014
COMMITMENTS [Abstract]
COMMITMENTS	NOTE 5 – COMMITMENTS
	The Company is obligated under an operating lease for office and laboratory space expiring in approximately 4 years. The aggregate minimum future lease payments under the operating leases are as follows:
	DECEMBER 31,	AMOUNT
	2015	$	68,451
	2016		47,407
	2017		48,817
	2018		50,274
	2019		6,307
	TOTAL	$	221,256
	Rent expense approximating $98,501 and $12,777 is included in research and development and general and administrative expenses for the year ended December 31, 2014. The rent expense for the year ended December 31, 2013 is $77,994 and is included in research and development expenses.

INCOME_TAXES

INCOME TAXES	12 Months Ended
	Dec. 31, 2014
INCOME TAXES [Abstract]
INCOME TAXES	NOTE 6 – INCOME TAXES
	As discussed in Note 1, the Company utilizes the asset and liability method of accounting for income taxes in accordance with FASB ASC 740.
	The income tax benefit (provision) consists of the following:
		2014			2013
	Current	$	(1,582,000	)	$	(1,345,000	)
	Deferred		(211,000	)		(370,000	)
	Change in valuation allowance		1,793,000			1,715,000
		$	—		$	—
	The reconciliation of the statutory federal rate to the Company's effective income tax rate is as follows:
		2014						2013
		Amount			%			Amount			%
	Income tax benefit at U.S. federal income tax rate	$	(1,503,000	)		(34	)	$	(1,330,000	)		(34	)
	State tax, net of federal tax effect		(398,000	)		(9	)		(352,000	)		(9	)
	Non-deductible share-based compensation		91,000			2			(33,000	)		(1	)
	Other non-deductible		17,000			—			—			—
	Change in valuation allowance		1,793,000			41			1,715,000			44
		$	—			—		$	—			—
	The components of deferred tax assets as of December 31, 2014 and 2013 are as follows:
		2014			2013
	Deferred tax asset for NOL carryforwards	$	11,574,000		$	9,992,000
	Share-based compensation		3,564,000			3,335,000
	Accrued expenses		—			17,000
	Valuation allowance		(15,138,000	)		(13,344,000	)
		$	—		$	—
	The valuation allowance for deferred tax assets as of December 31, 2014 and 2013 was $15,138,000 and $13,344,000, respectively. The change in the total valuation for the years ended December 31, 2014 and 2013 was an increase of $1,793,000 and $1,715,000, respectively. In assessing the realization of deferred tax assets, management considers whether it is more likely than not that some portion or all of the deferred tax assets will not be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the periods in which the net operating losses and temporary differences become deductible. Management considered projected future taxable income and tax planning strategies in making this assessment. The value of the deferred tax assets was offset by a valuation allowance, due to the current uncertainty of the future realization of the deferred tax assets.
	As of December 31, 2014, the Company had net operating loss carry forwards of approximately $26,900,000, expiring through the year ending December 31, 2034. This amount can be used to offset future taxable income of the Company.
	The timing and manner in which the Company can utilize operating loss carryforwards in any year may be limited by provisions of the Internal Revenue Code regarding changes in ownership of corporations. Such limitation may have an impact on the ultimate realization of its carryforwards and future tax deductions.
	On January 1, 2007, the Company adopted FASB ASC 740.10, which provides guidance for the recognition and measurement of certain tax positions in an enterprise's financial statements. Recognition involves a determination of whether it is more likely than not that a tax position will be sustained upon examination with the presumption that the tax position will be examined by the appropriate taxing authority having full knowledge of all relevant information. The adoption of FASB ASC 740.10 did not require an adjustment to the Company's financial statements.
	The Company's policy is to record interest and penalties associated with unrecognized tax benefits as additional income taxes in the statement of operations. As of January 1, 2014, the Company had no unrecognized tax benefits and no charge during 2014, and accordingly, the Company did not recognize any interest or penalties during 2014 related to unrecognized tax benefits. There is no accrual for uncertain tax positions as of December 31, 2014.
	The Company files U.S. income tax returns and a state income tax return. With few exceptions, the U.S. and state income tax returns filed for the tax years ending on December 31, 2011 and thereafter are subject to examination by the relevant taxing authorities.

STOCKHOLDERS_EQUITY

STOCKHOLDERS' EQUITY	12 Months Ended
	Dec. 31, 2014
STOCKHOLDERS' EQUITY [Abstract]
STOCKHOLDERS' EQUITY	NOTE 7 – STOCKHOLDERS' EQUITY
	Preferred Stock
	Pursuant to the Company's Articles of Incorporation, the Company's board of directors is empowered, without stockholder approval, to issue series of preferred stock with any designations, rights and preferences as they may from time to time determine. The rights and preferences of this preferred stock may be superior to the rights and preferences of the Company's common stock; consequently, preferred stock, if issued could have dividend, liquidation, conversion, voting or other rights that could adversely affect the voting power or other rights of the common stock. Additionally, preferred stock, if issued could be utilized, under special circumstances, as a method of discouraging, delaying or preventing a change in control of the Company's business or a takeover from a third party.
	Common Stock and Warrants
	During November 2007, under the 2007 Employee Stock Option Plan, the Company issued options to purchase 1,752,000 shares of common stock at a purchase price of $0.72 per share. The options expire in 5 years with 146,000 shares vesting each quarter from date of grant. During 2008, an option to purchase 750,000 shares of common stock, of which 125,000 shares were vested, forfeited. In November 2012, the remaining options were extended to November 2014. In October 2014, the remaining options were extended to November 2016. The incremental increase in fair value of the modified options was $245,082 using the Black-Scholes Option Pricing Formula which was expensed immediately.
	In January 2008, under the 2007 Employee Stock Option Plan, the Company issued an option to purchase 100,000 shares of common stock at a purchase price of $0.72 per share, vesting 25,000 immediately and the remaining in annual equal installments of 25,000. In November 2012, the option was extended to January 2015. In October 2014, the option was extended to January 2017. The incremental increase in fair value of the modified options was $21,462 using the Black-Scholes Option Pricing Formula which was expensed immediately.
	During April 2008, the Company issued a warrant to purchase 600,000 shares of common stock at a purchase price of $0.73 per share for consulting services rendered. The warrant was valued at $976,193, fair value, using the Black-Scholes Option Pricing Formula, vesting immediately. For the year ended December 31, 2008, the Company recognized $976,193 in consulting expense. During January 2013, the warrant agreement was amended from 600,000 warrants to 400,000 shares at an exercise price of $0.73 expiring October 2013 and 200,000 shares were rescinded. The modification did not result in the recognition of any additional expense. In October 2013, the warrant to purchase 400,000 shares of common stock expired.
	In January 2009, an employee was granted with an option to purchase up to 25,000 shares of common stock at a purchase price of $.25 per share. Using the Black-Scholes Option Pricing Formula, the options were valued at $13,136, fair value. These options expire in 5 years and vest immediately. The expense recognized during 2009 is $13,136. In May 2010, the option was partially exercised to purchase 15,000 shares of common stock for proceeds of $3,750. In January 2014, the remaining 10,000 options were exercised to purchase 10,000 shares of common stock for proceeds of $2,500.
	In February 2009, an employee was granted with an option to purchase up to 25,000 shares of common stock at a purchase price of $.45 per share. Using the Black-Scholes Option Pricing Formula, the options were valued at valued at $9,583, fair value. These options expire in 5 years and vest immediately. The expense recognized during the year ending December 31, 2009 was $9,583. During December 2013, the options were fully exercised for proceeds of $11,250.
	In June 2009, an employee was granted with an option to purchase up to 25,000 shares of common stock at a purchase price of $.34 per share. Using the Black-Scholes Option Pricing Formula, the options were valued at valued at $21,085, fair value. These options expire in 5 years and vest immediately. The expense recognized during 2009 was $21,085. In May 2014, the option was fully exercised to purchase 25,000 shares of common stock for proceeds of $8,500.
	During June 2009, the Company issued a warrant to purchase 464,000 shares of common stock at a purchase price of $0.34 per share for accounting services rendered. The warrant was valued at $391,342 using the Black-Scholes Option Pricing Formula, vesting 46,400 immediately and the remaining on equal monthly installments of 23,200 over the next eighteen months. The warrant expires in 5 years. The expense is being recognized based on service terms of the agreement over a twenty two month period. The expense recognized during 2010 and 2009 was $213,459 and $177,883. In April 2010, the warrant was partially exercised to purchase 10,000 shares of common stock for proceeds of $3,450. In February 2012, the warrant was partially exercised to purchase 20,000 shares of common stock for proceeds of $6,900. In June 2013, the warrant was partially exercised to purchase 20,000 shares of common stock for proceeds of $6,900. In March 2014, warrants were exercised to purchase 250,000 shares of common stock for proceeds of $86,250. In June 2014, the remaining outstanding 164,000 warrants were exercised to purchase 164,000 shares of common stock for proceeds of $56,580.
	During 2010, the Company issued 1,500,000 shares of common stock and warrants to purchase 375,000 shares of common stock with 156,250 warrants expiring September 2011 and 218,750 warrants expiring December 2011 for proceeds of $1,500,000 in accordance to a private placement memorandum as amended on September 14, 2010. Pursuant to the terms of the offerings, up to 30 units were offered at the purchase price of $50,000 per unit, with each unit comprised of 50,000 shares and a warrant to purchase 12,500 shares of common stock at $1.25 per share. During September 2011, all warrants were extended one year expiring September 2012 and December 2012. In January 2012, some warrants were exercised to purchase 40,000 shares of common stock for proceeds of $50,000. During August 2012, all remaining warrants were extended six months expiring March 2013 and June 2013. During March 2013, 335,000 warrants were extended three months expiring June 2013 and September 2013. The extension did not result in the recognition of any additional expense. In March 2013, a warrant was exercised to purchase 12,500 shares of common stock for proceeds of $15,625. In June 2013, warrants to purchase 143,750 shares of common stock expired. The remaining warrants to purchase 178,750 shares of common stock expired as of September 30, 2013.
	In January 2011, the Company issued a warrant to a related party to purchase 10,000 shares of common stock for legal services at an exercise price of $1.25 per share. Using the Black-Scholes Option Pricing Formula, the warrants were valued at $10,453, fair value. These warrants expire in 3 years and vest immediately. The expense recognized during 2011 is $10,453. In January 2014, the warrant to purchase 10,000 shares of common stock forfeited.
	In May 2011, the Company has signed an agreement with an institutional investor to sell up to $20,000,000 of common stock. Under the agreement subject to certain conditions and at the Company's sole discretion, the institutional investor has committed to invest up to $20 million in the Company's common stock over a 30-month period. The Company filed a registration statement with the U.S. Securities and Exchange Commission covering the resale of the shares that may be issued to the institutional investor. The institutional investor is obligated to make purchases as the Company directs in accordance with the agreement, which may be terminated by the Company at any time, without cost or penalty. Sales of shares will be made in specified amounts and at prices that are based upon the market prices of the Company's common stock immediately preceding the sales to the institutional investor. The Company has issued 150,830 shares of common stock to the institutional investor as an initial commitment fee valued at $162,896, fair value and 301,659 shares of common stock are reserved for additional commitment fees to the institutional investor in accordance with the terms of the agreement. During June 2011 through December, 2014, the institutional investor purchased 5,352,671 shares of common stock for proceeds of $6,849,998. The Company issued 103,330 shares of common stock as additional commitment fee, valued at $168,556, fair value, leaving 198,329 in reserve for additional commitment fees. For the year ending December 31, 2013, the institutional investor purchased 1,628,386 shares of common stock for proceeds of $1,800,000 and the Company issued 27,153 shares of common stock as additional commitment fee, valued at $34,274, fair value. There were no purchases during the year ending December 31, 2014.
	In August 2011, the board of directors approved a grant to a new employee of an option to purchase up to 150,000 shares of common stock at a purchase price of $1.01 per share. Using the Black-Scholes Option Pricing Formula, the option was valued at $123,241, fair value. The option expires in 5 years and vests in equal quarterly installments of 12,500 over the next 3 years beginning November 1, 2011. The expense recognized during the year ending December 31, 2013, 2012 and 2011 is $13,531, $41,156 and $17,204. In August 2013, options to purchase 62,500 shares of common stock forfeited. During October 2013, 38,350 options were exercised for proceeds of $38,734 and the remaining 49,150 options forfeited.
	During 2011, the Company issued 1,000,000 shares of common stock and warrants to purchase 1,000,000 shares of common stock expiring September 2013 for proceeds of $1,000,000 in accordance to a private placement memorandum dated August 26, 2011. Pursuant to the terms of the offerings, up to 4 units were offered at the purchase price of $250,000 per unit, with each unit comprised of 250,000 shares and a warrant to purchase 125,000 shares of common stock at $1.00 per share and a warrant to purchase 125,000 shares of common stock at $1.25 per share. The warrants to purchase 500,000 shares of common stock at $1.00 and the warrants to purchase 500,000 shares of common stock at $1.25 per share expired in September 2013.
	In August 2012, the board of directors approved a grant to a new employee of an option to purchase up to 100,000 shares of common stock at a purchase price of $0.925 per share. Using the Black-Scholes Option Pricing Formula, the option was valued at $74,486, fair value. The option expires in 5 years with 12,500 vesting every 3 months from date of grant. The option is expensed over the vesting terms. For the years ending December 31, 2014, 2013 and 2012, the Company recognized $3,012, $37,242 and $15,611 of net expense. In February 2014, the option to purchase 25,000 shares of common stock forfeited. In May 2014, the option to purchase 75,000 shares of common stock forfeited.
	In August 2012, the board of directors approved a grant to a new employee of an option to purchase up to 50,000 shares of common stock at a purchase price of $0.93 per share. Using the Black-Scholes Option Pricing Formula, the option was valued at $37,486, fair value. The option expires in 5 years with 6,250 vesting every three months from date of grant. The option is expensed over the vesting terms. For the year ending December 31, 2012, the Company recognized $7,137 of expense. In July 2013, the option to purchase 31,250 shares of common stock forfeited. For the year ending December 31, 2013, the Company recognized net expense of $6,920. In October 2013, the option to purchase 18,750 shares of common stock forfeited.
	In March 2013, the board of directors approved a grant to a new employee of an option to purchase up to 75,000 shares of common stock at a purchase price of $1.16 per share. Using the Black-Scholes Option Pricing Formula, the option was valued at $81,076, fair value. The option expires in 10 years with 9,375 vesting quarterly from date of grant. The option is expensed over the vesting terms. For the year ending December 31, 2014 and 2013, the Company recognized $40,539 and $33,986 of expense. As of December 31, 2014, options to purchase 75,000 shares of common stock are still outstanding.
	In May 2013, the board of directors approved a grant to a new employee of an option to purchase up to 10,000 shares of common stock at a purchase price of $1.03 per share. Using the Black-Scholes Option Pricing Formula, the option was valued at $9,574, fair value. The option expires in 10 years with 1,250 vesting quarterly from date of grant. The option is expensed over the vesting terms. In December 2013, the option to purchase 7,500 shares of common stock forfeited. For the year ending December 31, 2014 and 2013, the Company recognized a net expense of $0 and $2,394. In March 2014, the options to purchase 2,500 shares of common stock forfeited.
	In May 2013, the board of directors approved a grant to an employee of an option to purchase up to 100,000 shares of common stock at a purchase price of $1.00 per share. Using the Black-Scholes Option Pricing Formula, the option was valued at $80,824, fair value. The option expires in 10 years with 25,000 vesting August 1, 2013, October 1, 2013 and quarterly thereafter. The option is expensed over the vesting terms. For the year ending December 31, 2014 and 2013, the Company recognized $20,425 and $60,399 of expense. As of December 31, 2014, options to purchase 100,000 shares of common stock are still outstanding.
	In June 2013, the Company signed a Purchase Agreement and Registration Rights Agreement with an institutional investor to sell up to $20,000,000 of common stock. Under the agreement subject to certain conditions and at the Company's sole discretion, the institutional investor has committed to invest up to $20,000,000 in the Company's common stock over a 30-month period. The Company filed the registration statement with the U.S. Securities and Exchange Commission in September 2013. The institutional investor is obligated to make purchases as the Company directs in accordance with the agreement, which may be terminated by the Company at any time, without cost or penalty. Sales of shares will be made in specified amounts and at prices that are based upon the market prices of the Company's common stock immediately preceding the sales to the institutional investor. The Company issued 200,000 shares of restricted common stock to the institutional investor as an initial commitment fee valued at $170,000, fair value and 400,000 shares of common stock are reserved for additional commitment fees to the institutional investor in accordance with the terms of the agreement. During June 2013 through December 2014, the institutional investor purchased 1,563,648 shares of common stock for proceeds of $1,514,647 and the Company issued 23,272 shares of common stock as additional commitment fee, valued at $24,745, fair value, leaving 376,728 in reserve for additional commitment fees. For the year ending December 31, 2014, the institutional investor purchased 1,063,648 shares of common stock for proceeds of $1,036,148 and the Company issued 15,630 shares of common stock as additional commitment fee, valued at $16,862, fair value. For the year ending December 31, 2013, the institutional investor purchased 500,000 shares of common stock for proceeds of $478,500 and the Company issued 7,642 shares of common stock as additional commitment fee, valued at $7,882, fair value.
	During July 2013, the Company issued a warrant to purchase 100,000 shares of common stock at a purchase price of $0.90 per share for accounting services rendered commencing July 1, 2013. The warrant was valued at $48,915 using the Black-Scholes Option Pricing Formula, vesting over the next twelve months with 8,333 vesting each month for the first eleven months and 8,337 vesting the twelfth month from date of grant. The warrant expires in five years. The expense is being recognized based on service terms of the agreement over a twelve month period. For the year ending December 31, 2014 and 2013, the Company recognized $24,257 and $24,658 of expense. As of December 31, 2014, warrant to purchase 100,000 shares of common stock is still outstanding.
	During August 2013, the Company issued an option to an employee to purchase 25,000 shares of common stock at a purchase price of $0.84 per share. The option was valued at $17,852 using the Black-Scholes Option Pricing Formula. The option expires in ten years and vests immediately. The option is expensed over the vesting terms. For the year ending December 31, 2013, the Company recognized $17,852 of expense. As of December 31, 2014, the option to purchase 25,000 shares of common stock is still outstanding.
	During August 2013, the Company issued an option to a director to purchase 50,000 shares of common stock at a purchase price of $0.84 per share. The option was valued at $35,704 using the Black-Scholes Option Pricing Formula, vesting 20,000 options immediately and 10,000 options vesting in three equal quarterly installments commencing October 1, 2013. The option expires in ten years. The option is expensed over the vesting terms. For the year ending December 31, 2014 and 2013, the Company recognized $7,219 and $28,485 of expense. As of December 31, 2014, the option to purchase 50,000 shares of common stock is still outstanding.
	In October 2013, the Company issued an option to a new director to purchase 200,000 shares of common stock at a purchase price of $0.93 per share for a directorship commencing November 1, 2013. The option was valued at $174,106 using the Black-Scholes option pricing model. The option expires in 10 years with 50,000 vesting in annual installments commencing November 1, 2013. The option is expensed over the vesting terms. For the year ending December 31, 2014 and 2013, the Company recognized $43,527 and $50,801 of expense. As of December 31, 2014, the option to purchase 200,000 shares of common stock is still outstanding.
	In December 2013, the board of directors approved a grant to a senior advisor effective January 2014 of a warrant to purchase up to 100,000 shares of common stock at a purchase price of $0.715 per share. Using the Black-Scholes Option Pricing Formula, the warrant was valued at $53,313, fair value. The warrant expires in 5 years and vests 25,000 immediately and the remaining in equal monthly installments of 7,500 over the next 10 months. The warrant is expensed over the vesting terms. For the year ending December 31, 2014 and 2013, the Company recognized $53,313 and $0 of expense. As of December 31, 2014, the warrants to purchase 100,000 shares of common stock are still outstanding.
	In January 2014, the Company issued options to the Company's 4 independent directors to each purchase 50,000 shares of common stock at a purchase price of $0.715 per share. The options were each valued at $29,440, fair value, using the Black-Scholes Option Pricing Formula. The options expire in 10 years with 20,000 vesting immediately and the remainder vesting in quarterly equal installments of 10,000 commencing April 1, 2014. The options are expensed over the vesting terms. For the year December 31, 2014, the Company recognized $117,760 of expense. As of December 31, 2014, the options to purchase 200,000 shares of common stock are still outstanding.
	In March 2014, the Company issued options to a new employee to purchase 30,000 shares of common stock at a purchase price of $0.92 per share. The options were valued at $23,304, fair value, using the Black-Scholes Option Pricing Formula. The options expire in 10 years vesting in quarterly equal installments of 3,750 from date of employment. The options are expensed over the vesting terms. For the year ending December 31, 2014, the Company recognized $10,100 of expense. As of December 31, 2014, the options to purchase 30,000 shares of common stock are still outstanding.
	In March 2014, the Company issued options to a new employee to purchase 75,000 shares of common stock at a purchase price of $0.92 per share. The options were valued at $58,384, fair value, using the Black-Scholes Option Pricing Formula. The options expire in 10 years vesting in quarterly equal installments of 9,375 from date of employment. The options are expensed over the vesting terms. For the year ending December 31, 2014, the Company recognized $24,829 of expense. As of December 31, 2014, the options to purchase 75,000 shares of common stock are still outstanding.
	In March 2014, the Company issued options to a new employee to purchase 50,000 shares of common stock at a purchase price of $0.92 per share. The options were valued at $38,922, fair value, using the Black-Scholes Option Pricing Formula. The options expire in 10 years vesting in quarterly equal installments of 6,250 from date of employment. The options are expensed over the vesting terms. For the year ending December 31, 2014, the Company recognized $16,164 of expense. As of December 31, 2014, the options to purchase 50,000 shares of common stock are still outstanding.
	In March 2014, the Company issued options to an employee to purchase 125,000 shares of common stock at a purchase price of $0.92 per share. The options were valued at $96,211, fair value, using the Black-Scholes Option Pricing Formula. The options expire in 10 years vesting in quarterly equal installments of 15,625 commencing April 1, 2014. The options are expensed over the vesting terms. For the year ending December 31, 2014, the Company recognized $47,975 of expense. As of December 31, 2014, the options to purchase 125,000 shares of common stock are still outstanding.
	In March 2014, the Company issued options to an employee to purchase 30,000 shares of common stock at a purchase price of $0.92 per share. The options were valued at $22,222, fair value, using the Black-Scholes Option Pricing Formula. The options expire in 10 years vesting in quarterly equal installments of 7,500 commencing April 1, 2014. The options are expensed over the vesting terms. For the year ending December 31, 2014, the Company recognized $22,162 of expense. As of December 31, 2014, the options to purchase 30,000 shares of common stock are still outstanding.
	In March 2014, the Company issued options to purchase 40,000 shares of common stock at a purchase price of $0.92 per share to its Chief Executive Officer as part of a new employment agreement. The options were valued at $29,630, fair value, using the Black-Scholes Option Pricing Formula. The options expire in 10 years vesting in quarterly equal installments of 10,000 commencing April 1, 2014. The options are expensed over the vesting terms. For the year ending December 31, 2014, the Company recognized $29,550 of expense. As of December 31, 2014, the options to purchase 40,000 shares of common stock are still outstanding.
	In March 2014, the Company issued warrants to purchase 100,000 shares of common stock for consulting services at an exercise price of $0.92 per share. The warrants were valued at $66,936, fair value, using the Black-Scholes Option Pricing Formula. The warrants expire in 5 years vesting 25,000 immediately with the remaining 75,000 vesting in monthly equal installments of 7,500 commencing April 1, 2014. The warrants are expensed over the vesting terms. For the year ending December 31, 2014, the Company recognized $39,061 of expense. In October 2014, warrants to purchase 22,500 shares of common stock forfeited. As of December 31, 2014, the warrants to purchase 77,500 shares of common stock are still outstanding.
	In May 2014, the Company issued options to a new director to purchase 200,000 shares of common stock at a purchase price of $0.763 per share. The options were valued at $122,515 using the Black-Scholes Option Pricing Formula. The options expire in 10 years with 50,000 vesting immediately and the remainder vesting in annual equal installments of 50,000 commencing on the one year anniversary of the date of grant. The options are expensed over the vesting terms. For the year ending December 31, 2014, the Company recognized $50,264 of expense. As of December 31, 2014, the option to purchase 200,000 shares of common stock are still outstanding.
	During June 2014 through August 2014, the Company issued 4,207,600 shares of common stock and warrants to purchase 4,207,600 shares of common stock expiring five years from the date of purchase, for proceeds of $3,140,000 in accordance to a private placement memorandum as amended on May 27, 2014. Pursuant to the terms of the offerings, up to 60 units were offered at the purchase price of $50,000 per unit, with each unit comprised of 67,000 shares and a warrant to purchase 33,500 shares of common stock at $1.00 per share and a warrant to purchase 33,500 shares of common stock at $1.25 per share. The warrants to purchase 2,103,800 shares of common stock at $1.00 per share are still outstanding as of December 31, 2014. The warrants to purchase 2,103,800 shares of common stock at $1.25 per share are still outstanding as of December 31, 2014. Since the warrants are considered indexed to its own stock and qualify for equity classification, there is no requirement to separately account for the warrants. On September 9, 2014 the Company filed the Registration Statement on Form S-1 which became effective on September 17, 2014.
	During June 2014, July 2014, August 2014, September 2014, October 2014, November 2014 and December 2014, the Company issued 2,371, 2,081, 1,897, 2,121, 2,408, 2,322 and 2,487 shares of common stock, respectively to a director serving as a member of the Company's Operations Committee valued each issuance at $2,000, fair value. For the year ending December 31, 2014, the Company recognized $14,000 of expense. During January and February 2015, the Company issued 2,524 and 2,576 shares of common stock to the director serving as a member of the Company's Operations Committee valued at $4,000, fair value.
	During July 2014, the Company issued a warrant to purchase 100,000 shares of common stock at a purchase price of $0.95 per share for accounting services rendered commencing July 1, 2014. The warrant was valued at $63,576 using the Black-Scholes Option Pricing Formula, vesting over the next twelve months with 8,333 vesting immediately, 8,333 vesting per month on the first day of the next ten months and 8,337 vesting on the first day of the twelfth month of the corresponding service agreement. The warrant expires in five years. The expense is being recognized based on service terms of the agreement over a twelve month period. For the year ending December 31, 2014, the Company recognized $32,050 of expense. As of December 31, 2014, the warrants to purchase 100,000 shares of common stock are still outstanding.
	Effective August 21, 2014, the number of shares of the Company's common stock available for issuance under the 2007 Employee Stock plan was increased from 8,000,000 to 10,000,000 shares.
	In November 2014 and December, 2014, the Company issued 6,250 and 6,250 shares of common stock, respectively to a firm for investor relations services valued at $5,437 and $5,063, respectively, fair value. For the year ending December 31, 2014, the Company recognized $10,500 of investor relations expense. In January, February and March 2015, the Company issued 6,250, 6,250 and 6,250 shares of common stock, respectively valued at $5,056, $4,938 and $5,250 fair value.

STOCK_BASED_COMPENSATION

STOCK BASED COMPENSATION	12 Months Ended
	Dec. 31, 2014
STOCK BASED COMPENSATION [Abstract]
STOCK BASED COMPENSATION	NOTE 8 – STOCK BASED COMPENSATION
	The Company uses the Black-Scholes option pricing model to calculate the grant-date fair value of an award, with the following assumptions for 2014 and 2013: no dividend yield in both years, expected volatility, based on the Company's historical volatility, 70.25% to 109% in 2014 and between 107% to 113% in 2013, risk-free interest rate between 0.58% to 2.08% in 2014 and between 0.94% to 1.86% in 2013 and expected option life of 2.13 to 7.25 years in 2014 and 3 to 10 years in 2013.
	As of December 31, 2014, there was $324,004 of unrecognized compensation expense related to non-vested market-based share awards that is expected to be recognized through May 2017.
	The following tables summarize all stock option and warrant activity of the Company during the year ended December 31, 2014 and 2013:
		Non-Qualified Stock Options and Warrants
		Outstanding and Exercisable
		Number of				Exercise		Weighted Average
		Shares				Price		Exercise Price
	Outstanding, December 31, 2012		8,773,500				$0.25 - $1.75		$1.13
	Granted		560,000				$0.84 - $1.16		$0.96
	Expired		(1,971,650	)			$0.73 - $1.25		$1.02
	Forfeited		(120,000	)			$0.93 - $1.03		$0.99
	Exercised		(95,850	)			$0.345 - $1.25		$0.76
	Outstanding, December 31, 2013		7,146,000				$0.25 - $1.75		$1.16
	Granted		5,257,600				$0.72 - $1.25		$1.07
	Expired		(10,000	)			$1.25		$1.25
	Forfeited		(125,000	)			$0.92 - $1.03		$0.93
	Exercised		(449,000	)			$0.25 - $0.345		$0.34
	Outstanding, December 31, 2014		11,819,600				$0.63 - $1.75		$1.15
	Exercisable, December 31, 2014		11,267,723				$0.63 - $1.75		$1.16
	The aggregate intrinsic value of options and warrants outstanding and exercisable as of December 31, 2014 was $92,950. The aggregate intrinsic value is calculated as the difference between the exercise price of the underlying options and warrants and the closing stock price of $.77 for our common stock on December 31, 2014. The total intrinsic value of options and warrants exercised during the year ended December 31, 2014 and 2013 was $232,139 and $32,139.
	Non-Qualified Stock Options and Warrants Outstanding
	Range of	Number Outstanding			Weighted Average		Weighted Average
	Exercise Prices	Currently Exercisable			Remaining		Exercise Price of Options and
		at December 31, 2014			Contractual Life		Warrants Currently Exercisable
	$0.63 - $1.75	11,267,723			3.58 Years		$1.16

RELATED_PARTY

RELATED PARTY	12 Months Ended
	Dec. 31, 2014
RELATED PARTY [Abstract]
RELATED PARTY	NOTE 9 – RELATED PARTY
	At December 31, 2014 the Company had a legal accrual to related party of $8,258 and travel and office expense accruals of officers in the amount of $1,144. At December 31, 2013 the Company had accrued salaries to two beneficial owners of $42,088, a legal accrual to related party of $5,500 and travel and office expense accruals of officers in the amount of $1,229.

RETIREMENT_PLAN

RETIREMENT PLAN	12 Months Ended
	Dec. 31, 2014
RETIREMENT PLAN [Abstract]
RETIREMENT PLAN	NOTE 10 – RETIREMENT PLAN
	The Company established a 401(k) retirement plan covering all eligible employees beginning November 15, 2013. There were no contributions charged to expense in 2014 and 2013.

SUBSEQUENT_EVENTS

SUBSEQUENT EVENTS	12 Months Ended
	Dec. 31, 2014
SUBSEQUENT EVENTS [Abstract]
SUBSEQUENT EVENTS	NOTE 11 – SUBSEQUENT EVENTS
	In December 2014, the board of directors approved a grant to a senior advisor effective January 1, 2015 of a warrant to purchase up to 100,000 shares of common stock at a purchase price of $0.77 per share. Using the Black-Scholes Option Pricing Formula, the warrant was valued at $48,656, fair value. The warrant expires in 5 years and vests 25,000 immediately and the remaining in equal monthly installments of 7,500 over the next 10 months. The warrant is expensed over the vesting terms.
	In December 2014, the board of directors approved a grant to an employee effective January 1, 2015 to purchase 15,000 shares of common stock at a purchase price of $0.77 per share. The options were valued at $7,362 using the Black-Scholes Option Pricing Formula. The options expire in 10 years vesting 7,500 immediately and 7,500 in 3 months from the effective date of the option agreement. The options are expensed over the vesting terms.
	In January 2010, the Company issued a warrant to purchase 650,000 shares of common stock at a purchase price of $1.51 per share to a new member of its board of directors serving as the Company's full-time non-executive chair of the board of directors. Using the Black-Scholes Option Pricing Formula, the warrants were valued at $1,188,000, fair value, vesting 162,500 immediately and the remaining in annual equal installments of 162,500 over the next three years. The warrant expires in 5 years. During 2011, the warrant to purchase 650,000 shares of common stock, of which 487,500 shares were vested, forfeited. For the year ending December 31, 2011 and 2010, the Company recognized $306,765 and $580,167 of expense. The warrant to purchase 487,500 shares of common stock expired in January 2015.
	In March 2015, the Delaware laboratory lease was extended to March 2017 at an annual lease of $71,662.
	In March 2015, the Company issued options to the Company's 5 independent directors to each purchase 50,000 shares of common stock at a purchase price of $0.80 per share. The options were each valued at $24,901 using the Black-Scholes Option Pricing Formula. The options expire in 10 years with 20,000 vesting immediately and the remainder vesting in quarterly equal installments of 10,000 commencing April 1, 2015. The options are expensed over the vesting terms.
	In March 2015, the Company issued an option to an employee to purchase 2,500 shares of common stock at a purchase price of $0.80 per share. The option was valued at $1,231 using the Black-Scholes Option Pricing Formula. The option expires in 10 years vesting immediately. The option is expensed over the vesting terms.

SUMMARY_OF_SIGNIFICANT_ACCOUNT1

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)	12 Months Ended
	Dec. 31, 2014
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES [Abstract]
History and Nature of Business	History and Nature of Business
	Lightwave Logic, Inc. is a technology Company focused on the development of next generation photonic devices and non-linear optical polymer materials systems for applications in high speed fiber-optic data communications and optical computing markets. Currently the Company is in various stages of photonic device and materials development and evaluation with potential customers and strategic partners. The Company expects the next revenue stream to be in sales of non-linear optical polymers, prototype devices and product development agreements prior to moving into production.
	The Company's current development activities are subject to significant risks and uncertainties, including failing to secure additional funding to operationalize the Company's technology now under development.
	Lightwave Logic, Inc., formerly Third-Order Nanotechnologies, Inc., formerly PSI-Tec Holdings, Inc., formerly Eastern Idaho Internet Service, Inc. (the "Company") was organized under the laws of the State of Nevada in 1997. The Company was engaged in the business of marketing internet services until June 30, 1998, at which time the principal assets of the business were sold and operations were discontinued. The Company was inactive until the acquisition of PSI-TEC Corporation ("PSI-TEC") on July 14, 2004, at which time the name was changed to PSI-TEC Holdings, Inc.
Merger	Merger
	On July 14, 2004, the Company acquired PSI-TEC. Under the terms of the merger agreement, the stockholders of PSI-TEC received 15,600,000 shares of common stock in exchange for its 2,206,280 shares. Following the merger, the Company changed its name to PSI-TEC Holdings, Inc. Under accounting principles generally accepted in the United States, the share exchange is considered to be a capital transaction in substance rather than a business combination. That is, the share exchange is equivalent to the issuance of stock by PSI-TEC Holdings, Inc. for the net monetary assets of PSI-TEC, accompanied by a recapitalization, and is accounted for as a change of capital structure. Accordingly, the accounting for the share exchange was identical to that resulting from a reverse acquisition, except no goodwill was recorded. Under reverse takeover accounting, the post-reverse acquisition comparative historical financial statements of the legal acquirer, PSI-TEC Holdings, Inc., are those of the legal acquiree, PSI-TEC, which is considered to be the accounting acquirer. On October 20, 2006, PSI-TEC Holdings, Inc. and PSI-TEC merged and changed its name to Third-Order Nanotechnologies, Inc. On March 10, 2008, Third-Order Nanotechnologies, Inc. changed its name to Lightwave Logic, Inc.
Basis of Presentation	Basis of Presentation
	The financial statements are presented in accordance with Financial Accounting Standards Board of Accounting Standards Codification ("FASB ASC") 915 for development stage companies. The accompanying financial statements are presented in accordance with accounting principles generally accepted in the United States of America.
Estimates	Estimates
	The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying disclosures. Although these estimates are based on management's best knowledge of current events and actions the Company may undertake in the future, actual results could differ from the estimates.
Cash Equivalents	Cash Equivalents
	For the purposes of the statement of cash flows, the Company considers all highly liquid instruments with maturities of three months or less at the time of purchase to be cash equivalents.
Concentration of Credit Risk	Concentration of Credit Risk
	Certain financial instruments potentially subject the Company to concentrations of credit risk. These financial instruments consist primarily of cash. At December 31, 2014, the Company did have deposits with a financial institution that exceed the Federal Depository Insurance coverage.
Property and Equipment	Property and Equipment
	Equipment is stated at cost. Depreciation is principally provided by use of straight-line methods for financial and tax reporting purposes over the estimated useful lives of the assets, generally 5 years. When property is retired or otherwise disposed of, the cost and accumulated depreciation are removed from the accounts and any resulting gain or loss is included in operations.
Intangible Assets	Intangible Assets
	Definite-lived intangible assets are stated at cost. Patents are amortized over their estimated useful lives, generally 20 years. When certain patent applications are abandoned by the Company for claims that are covered by patents already granted to the Company, the cost of patent applications and accumulated amortization are removed from the accounts and the resulting expense is reflected in the statement of operations.
Fair Value of Financial Instruments	Fair Value of Financial Instruments
	The Company's financial instruments consist of cash, accounts payable and accrued expenses. The carrying values of cash, accounts payable and accrued expenses approximate fair value because of their short maturities.
Income Taxes	Income Taxes
	The Company follows FASB ASC 740, "Income Taxes," which requires an asset and liability approach to financial accounting and reporting for income taxes. Deferred income tax assets and liabilities are computed annually for temporary differences between the financial statement and tax bases of assets and liabilities that will result in taxable or deductible amounts in the future based on enacted tax laws and rates applicable to the periods in which the differences are expected to affect taxable income. Valuation allowances are established when necessary to reduce deferred tax assets to the amount expected to be realized. Income tax expense is the tax payable or refundable for the period plus or minus the change during the period in deferred tax assets and liabilities.
Stock-based Payments	Stock-based Payments
	The Company accounts for stock-based compensation under the provisions of FASB ASC 718, "Compensation - Stock Compensation" which requires the measurement and recognition of compensation expense for all stock-based awards made to employees and directors based on estimated fair values on the grant date. The Company estimates the fair value of stock-based awards on the date of grant using the Black-Scholes model. The value of the portion of the award that is ultimately expected to vest is recognized as expense over the requisite service periods using the straightline method. The Company accounts for stock-based compensation awards to nonemployees in accordance with FASB ASC 505-50, "Equity-Based Payments to Non-Employees (“ASC 505-50”). Under ASC 505-50, the Company determines the fair value of the warrants or stock-based compensation awards granted as either the fair value of the consideration received or the fair value of the equity instruments issued, whichever is more reliably measurable. All issuances of stock options or other equity instruments to non-employees as consideration for goods or services received by the Company are accounted for based on the fair value of the equity instruments issued. Any stock options issued to non-employees are recorded as an expense and additional paid in capital in stockholders' equity over the applicable service periods.
Loss Per Share	Loss Per Share
	The Company follows FASB ASC 260, "Earnings per Share", resulting in the presentation of basic and diluted earnings per share. Because the Company reported a net loss in 2014 and 2013, common stock equivalents, including stock options and warrants were anti-dilutive; therefore, the amounts reported for basic and dilutive loss per share were the same.
Recoverability of Long Lived Assets	Recoverability of Long Lived Assets
	The Company follows FASB ASC 360, "Property, Plant, and Equipment". Long-lived assets to be held and used are reviewed for impairment whenever events or changes in circumstances indicate that the related carrying amount may not be recoverable. When required, impairment losses on assets to be held and used are recognized based on the excess of the asset's carrying amount.
Comprehensive Income	Comprehensive Income
	The Company follows FASB ASC 220.10, "Reporting Comprehensive Income." Comprehensive income is a more inclusive financial reporting methodology that includes disclosure of certain financial information that historically has not been recognized in the calculation of net income. Since the Company has no items of other comprehensive income, comprehensive income (loss) is equal to net loss.
Recently Adopted Accounting Pronouncements and Recently Issued Accounting Pronouncements Not Yet Adopted	Recently Adopted Accounting Pronouncements
	In June 2014, the FASB issued ASU No. 2014-10, "Development Stage Entities (Topic 915), Elimination of Certain Financial Reporting Requirements", including an Amendment to Variable Interest Entities Guidance in Topic 810, "Consolidation". The amendments in this Update remove the definition of a development stage entity from the Master Glossary of the Accounting Standards Codification, thereby removing the financial reporting distinction between development stage entities and other reporting entities from U.S. GAAP. In addition, the amendments eliminate the requirements for development stage entities to (1) present inception-to-date information in the statements of income, cash flows, and shareholder equity, (2) label the financial statements as those of a development stage entity, (3) disclose a description of the development stage activities in which the entity is engaged, and (4) disclose in the first year in which the entity is no longer a development stage entity that in prior years it had been in the development stage.
	The amendments also clarify that the guidance in Topic 275, "Risks and Uncertainties", is applicable to entities that have not commenced planned principal operations.
	The amendments related to the elimination of inception-to-date information and the other remaining disclosure requirements of Topic 915 should be applied retrospectively except for the clarification to Topic 275, which shall be applied prospectively. For public business entities, those amendments are effective for annual reporting periods beginning after December 15, 2014, and interim periods therein.
	For public business entities, the amendment eliminating the exception to the sufficiency-of-equity-at-risk criterion for development stage entities in paragraph 810-10-15-16 should be applied retrospectively for annual reporting periods beginning after December 15, 2015, and interim periods therein.
	Early application of each of the amendments is permitted for any annual reporting period or interim period for which the entity's financial statements have not yet been issued (public business entities) or made available for issuance (other entities). Upon adoption, entities will no longer present or disclose any information required by Topic 915.
	The Company adopted the amendments retrospectively beginning in interim period ending June 30, 2014.
	Recently Issued Accounting Pronouncements Not Yet Adopted
	In August 2014, the FASB issued ASU 2014-15, Presentation of Financial Statements – Going Concern (Subtopic 205-40), Disclosure of Uncertainties about an Entity's Ability to Continue as a Going Concern. The amendments in this Update provide guidance about management's responsibility to evaluate whether there are conditions or events, considered in the aggregate, that raise substantial doubt about the entity's ability to continue as a going concern within one year after the date that the financial statements are issued and to provide related footnote disclosures. Substantial doubt about an entity's ability to continue as a going concern exists when relevant conditions and events, considered in the aggregate, indicate that it is probable that the entity will be unable to meet its obligations as they become due within one year after the date that the financial statements are issued. The amendments in this Update are effective for the annual period ending after December 15, 2016, and for annual periods and interim periods thereafter. Early application is permitted.

PROPERTY_AND_EQUIPMENT_Tables

PROPERTY AND EQUIPMENT (Tables)	12 Months Ended
	Dec. 31, 2014
PROPERTY AND EQUIPMENT [Abstract]
Schedule of Property and Equipment
		December 31,		December 31,
		2014		2013
	Office equipment	$	51,322	$	24,244
	Lab equipment		544,858		474,049
	Furniture		18,782		4,061
	Leasehold improvements		136,900		37,519
			751,862		539,873
	Less: Accumulated depreciation		376,635		241,513
		$	375,227	$	298,360

INTANGIBLE_ASSETS_Tables

INTANGIBLE ASSETS (Tables)	12 Months Ended
	Dec. 31, 2014
INTANGIBLE ASSETS [Abstract]
Schedule of Patents
		December 31,		December 31,
		2014		2013
	Patents	$	660,586	$	579,235
	Less: Accumulated amortization		50,557		35,695
		$	610,029	$	543,540

COMMITMENTS_Tables

COMMITMENTS (Tables)	12 Months Ended
	Dec. 31, 2014
COMMITMENTS [Abstract]
Schedule of Future Lease Payments of Operating Leases
	DECEMBER 31,	AMOUNT
	2015	$	68,451
	2016		47,407
	2017		48,817
	2018		50,274
	2019		6,307
	TOTAL	$	221,256

INCOME_TAXES_Tables

INCOME TAXES (Tables)	12 Months Ended
	Dec. 31, 2014
INCOME TAXES [Abstract]
Schedule of Income Tax Benefit (Provision)
		2014			2013
	Current	$	(1,582,000	)	$	(1,345,000	)
	Deferred		(211,000	)		(370,000	)
	Change in valuation allowance		1,793,000			1,715,000
		$	—		$	—
Schedule of Reconciliation of Statutory Federal Rate to Effective Income Tax Rate
		2014						2013
		Amount			%			Amount			%
	Income tax benefit at U.S. federal income tax rate	$	(1,503,000	)		(34	)	$	(1,330,000	)		(34	)
	State tax, net of federal tax effect		(398,000	)		(9	)		(352,000	)		(9	)
	Non-deductible share-based compensation		91,000			2			(33,000	)		(1	)
	Other non-deductible		17,000			—			—			—
	Change in valuation allowance		1,793,000			41			1,715,000			44
		$	—			—		$	—			—
Schedule of Components of Deferred Tax Assets
		2014			2013
	Deferred tax asset for NOL carryforwards	$	11,574,000		$	9,992,000
	Share-based compensation		3,564,000			3,335,000
	Accrued expenses		—			17,000
	Valuation allowance		(15,138,000	)		(13,344,000	)
		$	—		$	—

STOCK_BASED_COMPENSATION_Table

STOCK BASED COMPENSATION (Tables)	12 Months Ended
	Dec. 31, 2014
STOCK BASED COMPENSATION [Abstract]
Schedule of Non-Qualified Stock Options and Warrants Outstanding and Exercisable
		Non-Qualified Stock Options and Warrants
		Outstanding and Exercisable
		Number of				Exercise		Weighted Average
		Shares				Price		Exercise Price
	Outstanding, December 31, 2012		8,773,500				$0.25 - $1.75		$1.13
	Granted		560,000				$0.84 - $1.16		$0.96
	Expired		(1,971,650	)			$0.73 - $1.25		$1.02
	Forfeited		(120,000	)			$0.93 - $1.03		$0.99
	Exercised		(95,850	)			$0.345 - $1.25		$0.76
	Outstanding, December 31, 2013		7,146,000				$0.25 - $1.75		$1.16
	Granted		5,257,600				$0.72 - $1.25		$1.07
	Expired		(10,000	)			$1.25		$1.25
	Forfeited		(125,000	)			$0.92 - $1.03		$0.93
	Exercised		(449,000	)			$0.25 - $0.345		$0.34
	Outstanding, December 31, 2014		11,819,600				$0.63 - $1.75		$1.15
	Exercisable, December 31, 2014		11,267,723				$0.63 - $1.75		$1.16
Schedule of Non-Qualified Stock Options and Warrants Outstanding, by Exercise Price Range
	Non-Qualified Stock Options and Warrants Outstanding
	Range of	Number Outstanding			Weighted Average		Weighted Average
	Exercise Prices	Currently Exercisable			Remaining		Exercise Price of Options and
		at December 31, 2014			Contractual Life		Warrants Currently Exercisable
	$0.63 - $1.75	11,267,723			3.58 Years		$1.16

SUMMARY_OF_SIGNIFICANT_ACCOUNT2

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details)	12 Months Ended	90 Months Ended	216 Months Ended
	Dec. 31, 2014	Jul. 13, 2004	Dec. 31, 2014
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES [Abstract]
Estimated useful lives of assets	5 years
Estimated useful life of patents	20 years
Date of incorporation	1-Jan-97	1-Jan-97
Entity former incorporation name	Third-Order Nanotechnologies, Inc., formerly PSI-Tec Holdings, Inc., formerly Eastern Idaho Internet Service, Inc.	PSI-Tec Holdings, Inc.
Jurisdiction of incorporation	Nevada	Nevada
Date of corporate name change	10-Mar-08		10-Mar-08
Disposal of assets discription		The Company was engaged in the business of marketing internet services until June 30, 1998, at which time the principal assets of the business were sold and operations were discontinued.
Date of acquisition			14-Jul-04
Fair value method for acquisition transaction			the share exchange is considered to be a capital transaction in substance rather than a business combination. That is, the share exchange is equivalent to the issuance of stock by PSI-TEC Holdings, Inc. for the net monetary assets of PSI-TEC, accompanied by a recapitalization, and is accounted for as a change of capital structure. Accordingly, the accounting for the share exchange was identical to that resulting from a reverse acquisition, except no goodwill was recorded. Under reverse takeover accounting, the post-reverse acquisition comparative historical financial statements of the legal acquirer, PSI-TEC Holdings, Inc.
Name of acquired entity			PSI-TEC Holdings, Inc.
Common shares issued by entity in acquisition transaction			15,600,000
Common shares exchanged			2,206,280
Date of merger			20-Oct-06

MANAGEMENTS_PLANS_Details

MANAGEMENT'S PLANS (Details) (USD $)	12 Months Ended
	Dec. 31, 2014
MANAGEMENT'S PLANS [Abstract]
Approximate cash position	$2,450,000
Approximate monthly expenditures	295,000
Agreement with an institutional investor to sell common stock and investor committed to invest in common stock (upper limit)	20,000,000
Term of agreement with institutional investor	30 months
Remaining available amount	$18,485,352

PROPERTY_AND_EQUIPMENT_Schedul

PROPERTY AND EQUIPMENT (Schedule of Equipment) (Details) (USD $)	Dec. 31, 2014	Dec. 31, 2013
Property, Plant and Equipment [Line Items]
Property and equipment, gross	$751,862	$539,873
Less: Accumulated depreciation	376,635	241,513
Property and equipment, net	375,227	298,360
Office equipment [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	51,322	24,244
Lab equipment [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	544,858	474,049
Furniture [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	18,782	4,061
Leasehold improvements [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	$136,900	$37,519

PROPERTY_AND_EQUIPMENT_Narrati

PROPERTY AND EQUIPMENT (Narrative) (Details) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
PROPERTY AND EQUIPMENT [Abstract]
Depreciation expense	$136,322	$111,912

INTANGIBLE_ASSETS_Schedule_of_

INTANGIBLE ASSETS (Schedule of Patents) (Details) (USD $)	Dec. 31, 2014	Dec. 31, 2013
INTANGIBLE ASSETS [Abstract]
Patents	$660,586	$579,235
Less: Accumulated amortization	50,557	35,695
Intangible assets - net	$610,029	$543,540

INTANGIBLE_ASSETS_Narrative_De

INTANGIBLE ASSETS (Narrative) (Details) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
INTANGIBLE ASSETS [Abstract]
Legal life of patents	20 years
Amortization expense	$14,861	$14,861
Expense for abandoned patents

COMMITMENTS_Details

COMMITMENTS (Details) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
COMMITMENTS [Abstract]
2015	$68,451
2016	47,407
2017	48,817
2018	50,274
2019	6,307
Total	221,256
Lease term	4 years
Research and development [Member]
COMMITMENTS [Abstract]
Rent expense	98,501	77,994
General and administrative [Member]
COMMITMENTS [Abstract]
Rent expense	$12,777

INCOME_TAXES_Schedule_of_Incom

INCOME TAXES (Schedule of Income Tax Benefit (Provision)) (Details) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
INCOME TAXES [Abstract]
Current	($1,582,000)	($1,345,000)
Deferred	-211,000	-370,000
Change in valuation allowance	1,793,000	1,715,000
Total

INCOME_TAXES_Schedule_of_Recon

INCOME TAXES (Schedule of Reconciliation of Statutory Federal Rate to Effective Income Tax Rate) (Details) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
INCOME TAXES [Abstract]
Income tax benefit at U.S. federal income tax rate	($1,503,000)	($1,330,000)
State tax, net of federal tax effect	-398,000	-352,000
Non-deductible share-based compensation	91,000	-33,000
Other non-deductible	17,000
Change in valuation allowance	1,793,000	1,715,000
Total
Income tax benefit at U.S. federal income tax rate	-34.00%	-34.00%
State tax, net of federal tax effect	-9.00%	-9.00%
Non-deductible share-based compensation	2.00%	-1.00%
Other non-deductible
Change in valuation allowance	41.00%	44.00%
Total

INCOME_TAXES_Schedule_of_Compo

INCOME TAXES (Schedule of Components of Deferred Tax Assets) (Details) (USD $)	Dec. 31, 2014	Dec. 31, 2013
INCOME TAXES [Abstract]
Deferred tax asset for NOL carryforwards	$11,574,000	$9,992,000
Share-based compensation	3,564,000	3,335,000
Accrued expenses		17,000
Valuation allowance	-15,138,000	-13,344,000
Total

INCOME_TAXES_Narrative_Details

INCOME TAXES (Narrative) (Details) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
INCOME TAXES [Abstract]
Deferred tax assets valuation allowance	$15,138,000	$13,344,000
Change in valuation allowance	1,793,000	1,715,000
Net operating loss carry forwards	$26,900,000
Net operating loss carry forwards expiration date	31-Dec-34

STOCKHOLDERS_EQUITY_Details

STOCKHOLDERS' EQUITY (Details) (USD $)

12 Months Ended

1 Months Ended

12 Months Ended

1 Months Ended

12 Months Ended

1 Months Ended

12 Months Ended

1 Months Ended

3 Months Ended

12 Months Ended

1 Months Ended

43 Months Ended

1 Months Ended

12 Months Ended

1 Months Ended

13 Months Ended

1 Months Ended

0 Months Ended

1 Months Ended

2 Months Ended

1 Months Ended

Dec. 31, 2014

Dec. 31, 2013

Oct. 31, 2014

Nov. 30, 2007

Dec. 31, 2008

Jan. 31, 2008

Jul. 31, 2013

Apr. 30, 2008

Oct. 31, 2013

Jan. 31, 2013

Jan. 31, 2014

31-May-10

Jan. 31, 2009

Dec. 31, 2009

Feb. 28, 2009

31-May-14

Jun. 30, 2009

Jul. 31, 2014

Jun. 30, 2014

Mar. 31, 2014

Jun. 30, 2013

Feb. 29, 2012

Apr. 30, 2010

Dec. 31, 2010

Sep. 30, 2013

Mar. 31, 2013

Aug. 30, 2012

Sep. 30, 2011

Jan. 31, 2012

Aug. 31, 2014

Dec. 31, 2011

Jan. 31, 2011

31-May-11

Dec. 31, 2014

Aug. 30, 2013

Aug. 30, 2011

Aug. 31, 2011

Dec. 31, 2012

Feb. 28, 2014

Aug. 31, 2012

Dec. 31, 2013

31-May-13

Jun. 30, 2014

Aug. 31, 2013

Jan. 31, 2010

Jan. 02, 2015

Dec. 31, 2014

Nov. 30, 2014

Sep. 30, 2014

Aug. 31, 2014

Feb. 28, 2015

Jan. 31, 2015

Feb. 28, 2015

Mar. 31, 2015

Aug. 21, 2014

Equity Issuance [Line Items]

Agreement with an institutional investor to sell common stock and investor committed to invest in common stock (upper limit)

$20,000,000

Term of agreement with institutional investor

30 months

Share issued, value

16,862

212,156

November 2007 Options Issuance [Member]

Equity Issuance [Line Items]

Number of common shares that can be purchased through option issuance

1,752,000

750,000

Purchase price of options issued

$0.72

Expiration period

5 years

Option granted, number of shares vesting in installments

146,000

Shares rescinded/forfeited

125,000

Stock option expense

245,082

Common stock available for issuance before August 21, 2014

8,000,000

Common stock available for issuance

10,000,000

January 2008 Options Issuance [Member]

Equity Issuance [Line Items]

Number of common shares that can be purchased through option issuance

100,000

Purchase price of options issued

$0.72

Option granted, number of shares vesting in installments

25,000

Stock option expense

21,462

Vesting immediately

25,000

Warrant Transaction for Consulting Services [Member]

Equity Issuance [Line Items]

Number of common shares that can be purchased through option issuance

600,000

Expiration period

5 years

Stock option expense

24,257

24,658

Exercise price of warrants

$0.90

$0.73

Fair value of warrant

48,915

976,193

Consulting expense

976,193

Frequency of vesting installments

with 8,333 vesting each month for the first eleven months and 8,337 vesting the twelfth month from date of grant

Vesting period

12 months

Number of common shares that can be purchased through warrant

100,000

Stock outstanding

100,000

100,000

100,000

Warrant agreement amendment [Member]

Equity Issuance [Line Items]

Number of common shares that can be purchased through option issuance

400,000

Shares rescinded/forfeited

200,000

Exercise price of warrants

$0.73

Shares Expired

400,000

Warrant expiration date

31-Oct-13

January 2009 New Employee [Member]

Equity Issuance [Line Items]

Expiration period

5 years

Stock option expense

13,136

Option granted, shares (upper limit)

25,000

Option granted, purchase price

$0.25

Option granted, value

13,136

Proceeds from issuance of common stock and warrants

2,500

3,750

Number of shares purchased

10,000

15,000

Exercise of options, shares

10,000

February 2009 New Employee [Member]

Equity Issuance [Line Items]

Expiration period

5 years

Stock option expense

9,583

Option granted, shares (upper limit)

25,000

Option granted, purchase price

$0.45

Option granted, value

9,583

Proceeds from issuance of common stock and warrants

11,250

June 2009 New Employee [Member]

Equity Issuance [Line Items]

Expiration period

5 years

Stock option expense

21,085

Option granted, shares (upper limit)

25,000

Option granted, purchase price

$0.34

Option granted, value

21,085

Proceeds from issuance of common stock and warrants

8,500

Number of shares purchased

25,000

Warrant Transaction for Accounting Services [Member]

Equity Issuance [Line Items]

Expiration period

5 years

5 years

Option granted, number of shares vesting in installments

23,200

8,337

Stock option expense

32,050

177,883

213,459

Vesting immediately

46,400

8,333

Exercise price of warrants

$0.34

$0.95

Fair value of warrant

391,342

63,576

Proceeds from issuance of common stock and warrants

56,580

86,250

6,900

6,900

3,450

Number of shares purchased

164,000

250,000

20,000

20,000

10,000

Frequency of vesting installments

monthly

Vesting period

18 months

12 months

Number of common shares that can be purchased through warrant

464,000

100,000

Warrants outstanding

100,000

164,000

100,000

164,000

100,000

2010 Common Stock and Warrants one [Member]

Equity Issuance [Line Items]

Exercise price of warrants

$1.25

Shares Expired

143,750

178,750

Proceeds from issuance of common stock and warrants

1,500,000

15,625

Stock issued to purchase common stock, warrants and monetary compensation

1,500,000

Number of shares purchased

12,500

Number of units offered (upper limit)

30

Price per unit

$50,000

Warrant expiration extention

3 months

6 months

1 year

Warrant expiration date, number of shares

335,000

Warrant expiration date

30-Jun-13

31-Mar-13

30-Sep-12

Warrant expiration date, transaction two

30-Sep-13

30-Jun-13

31-Dec-12

2010 Common Stock and Warrants one [Member] | Warrant One [Member]

Equity Issuance [Line Items]

Number of shares purchased

156,250

Warrant expiration date

30-Sep-11

2010 Common Stock and Warrants one [Member] | Warrant Two [Member]

Equity Issuance [Line Items]

Number of shares purchased

218,750

Warrant expiration date

31-Dec-11

Common Stock [Member]

Equity Issuance [Line Items]

Proceeds from issuance of common stock and warrants

50,000

Number of shares purchased

375,000

12,500

40,000

Units [Member]

Equity Issuance [Line Items]

Price per unit

$250,000

Number of shares comprising unit

50,000

67,000

Units [Member] | Warrant One [Member]

Equity Issuance [Line Items]

Number of common shares that can be purchased through option issuance

125,000

Exercise price of warrants

1

$1

Number of common shares that can be purchased through warrant

33,500

33,500

Units [Member] | Warrant Two [Member]

Equity Issuance [Line Items]

Number of common shares that can be purchased through option issuance

125,000

Exercise price of warrants

1.25

$1.25

Number of common shares that can be purchased through warrant

33,500

33,500

Warrant Transaction for Legal Services [Member]

Equity Issuance [Line Items]

Expiration period

3 years

Stock option expense

10,453

Exercise price of warrants

$1.25

Fair value of warrant

10,453

Exercise of options, shares

10,000

Number of common shares that can be purchased through warrant

10,000

Institutional Investor one [Member]

Equity Issuance [Line Items]

Proceeds from issuance of common stock and warrants

1,800,000

6,849,998

Number of shares purchased

1,628,386

5,352,671

Agreement with an institutional investor to sell common stock and investor committed to invest in common stock (upper limit)

20,000,000

Common stock issued to institutional investor as commitment fee, shares

27,153

150,830

103,330

Common stock issued to institutional investor as commitment fee

34,274

162,896

168,556

Common stock reserved for additional commitment fees to the institutional investor

301,659

198,329

August 2011 New Employee [Member]

Equity Issuance [Line Items]

Expiration period

5 years

Option granted, number of shares vesting in installments

12,500

Shares rescinded/forfeited

49,150

62,500

Stock option expense

13,531

17,204

41,156

Option granted, shares (upper limit)

150,000

Option granted, purchase price

$1.01

Option granted, value

123,241

Proceeds from issuance of common stock and warrants

38,734

Frequency of vesting installments

quarterly

Vesting period

3 years

Beginning date of shares vesting

1-Nov-11

Exercise of options, shares

38,350

2011 Common Stock and Warrants one [Member]

Equity Issuance [Line Items]

Proceeds from issuance of common stock and warrants

1,000,000

Number of units offered (upper limit)

4

Share issued, shares

1,000,000

Number of common shares that can be purchased through warrant

1,000,000

2011 Common Stock and Warrants one [Member] | Warrant One [Member]

Equity Issuance [Line Items]

Exercise price of warrants

$1

Shares Expired

500,000

2011 Common Stock and Warrants one [Member] | Warrant Two [Member]

Equity Issuance [Line Items]

Exercise price of warrants

$1.25

Shares Expired

500,000

August 2012 New Employee [Member]

Equity Issuance [Line Items]

Expiration period

5 years

Option granted, number of shares vesting in installments

12,500

Shares rescinded/forfeited

75,000

25,000

Stock option expense

3,012

37,242

15,611

Option granted, shares (upper limit)

100,000

Option granted, purchase price

$0.93

Option granted, value

74,486

Frequency of vesting installments

Every 3 months

August 2012 New Employee 1 [Member]

Equity Issuance [Line Items]

Expiration period

5 years

Option granted, number of shares vesting in installments

6,250

Shares rescinded/forfeited

18,750

31,250

Stock option expense

7,137

Option granted, shares (upper limit)

50,000

Option granted, purchase price

$0.93

Option granted, value

37,486

Frequency of vesting installments

Every three months

Stock option expense, net of forfeiture

6,920

March 2013 New Employee [Member]

Equity Issuance [Line Items]

Expiration period

10 years

Option granted, number of shares vesting in installments

9,375

Stock option expense

40,539

33,986

Option granted, shares (upper limit)

75,000

Option granted, purchase price

$1.16

Option granted, value

81,076

Frequency of vesting installments

Quarterly

Stock outstanding

75,000

75,000

75,000

May 2013 New Employee [Member]

Equity Issuance [Line Items]

Expiration period

10 years

Option granted, number of shares vesting in installments

1,250

Shares rescinded/forfeited

2,500

7,500

Stock option expense

0

2,394

Option granted, shares (upper limit)

10,000

Option granted, purchase price

$1.03

Option granted, value

9,574

Frequency of vesting installments

Quarterly

May 2013 New Employee 1 [Member]

Equity Issuance [Line Items]

Expiration period

10 years

Option granted, number of shares vesting in installments

25,000

Stock option expense

20,425

60,399

Option granted, shares (upper limit)

100,000

Option granted, purchase price

$1

Option granted, value

80,824

Frequency of vesting installments

August 1, 2013, October 1, 2013 and quarterly thereafter

Stock outstanding

100,000

100,000

100,000

Institutional Investor [Member]

Equity Issuance [Line Items]

Proceeds from issuance of common stock and warrants

1,036,148

478,500

1,514,647

Number of shares purchased

1,063,648

500,000

1,563,648

Common stock issued to institutional investor as commitment fee, shares

15,630

7,642

200,000

23,272

Common stock issued to institutional investor as commitment fee

16,862

7,882

170,000

24,745

Common stock reserved for additional commitment fees to the institutional investor

400,000

376,728

August 2013 New Employee 1 [Member]

Equity Issuance [Line Items]

Expiration period

10 years

Stock option expense

17,852

Option granted, shares (upper limit)

25,000

Option granted, purchase price

$0.84

Option granted, value

17,852

Stock outstanding

25,000

25,000

25,000

Director one [Member]

Equity Issuance [Line Items]

Expiration period

10 years

Option granted, number of shares vesting in installments

10,000

Stock option expense

7,219

28,485

Vesting immediately

20,000

Option granted, shares (upper limit)

50,000

Option granted, purchase price

$0.84

Option granted, value

35,704

Frequency of vesting installments

Quarterly

Beginning date of shares vesting

1-Oct-13

Stock outstanding

50,000

50,000

50,000

New Director Two [Member]

Equity Issuance [Line Items]

Expiration period

10 years

Option granted, number of shares vesting in installments

50,000

Stock option expense

43,527

50,801

Option granted, shares (upper limit)

200,000

Option granted, purchase price

0.93

Option granted, value

174,106

Frequency of vesting installments

Annual

Beginning date of shares vesting

1-Nov-13

Stock outstanding

200,000

200,000

200,000

Senior Advisor [Member]

Equity Issuance [Line Items]

Expiration period

5 years

Option granted, number of shares vesting in installments

7,500

Stock option expense

53,313

0

Vesting immediately

25,000

Exercise price of warrants

$0.72

0.715

Fair value of warrant

53,313

53,313

Frequency of vesting installments

Monthly

Vesting period

10 months

Number of common shares that can be purchased through warrant

100,000

100,000

100,000

100,000

100,000

Four Independent Directors [Member]

Equity Issuance [Line Items]

Expiration period

10 years

Option granted, number of shares vesting in installments

10,000

Stock option expense

117,760

Vesting immediately

20,000

Option granted, shares (upper limit)

50,000

Option granted, purchase price

$0.72

Option granted, value

29,440

Frequency of vesting installments

Quarterly

Beginning date of shares vesting

1-Apr-14

Stock outstanding

200,000

200,000

200,000

March 2014 New Employee 1 [Member]

Equity Issuance [Line Items]

Expiration period

10 years

Option granted, number of shares vesting in installments

3,750

Stock option expense

10,100

Option granted, shares (upper limit)

30,000

Option granted, purchase price

$0.92

Option granted, value

23,304

Frequency of vesting installments

Quarterly

Stock outstanding

30,000

30,000

30,000

March 2014 New Employee 2 [Member]

Equity Issuance [Line Items]

Expiration period

10 years

Option granted, number of shares vesting in installments

9,375

Stock option expense

24,829

Option granted, shares (upper limit)

75,000

Option granted, purchase price

$0.92

Option granted, value

58,384

Frequency of vesting installments

Quarterly

Stock outstanding

75,000

75,000

75,000

March 2014 New Employee 3 [Member]

Equity Issuance [Line Items]

Expiration period

10 years

Option granted, number of shares vesting in installments

6,250

Stock option expense

16,164

Option granted, shares (upper limit)

50,000

Option granted, purchase price

$0.92

Option granted, value

38,922

Frequency of vesting installments

Quarterly

Stock outstanding

50,000

50,000

50,000

March 2014 New Employee 4 [Member]

Equity Issuance [Line Items]

Expiration period

10 years

Option granted, number of shares vesting in installments

15,625

Stock option expense

47,975

Option granted, shares (upper limit)

125,000

Option granted, purchase price

$0.92

Option granted, value

96,211

Frequency of vesting installments

Quarterly

Beginning date of shares vesting

1-Apr-14

Stock outstanding

125,000

125,000

125,000

March 2014 New Employee 5 [Member]

Equity Issuance [Line Items]

Expiration period

10 years

Option granted, number of shares vesting in installments

7,500

Stock option expense

22,162

Option granted, shares (upper limit)

30,000

Option granted, purchase price

$0.92

Option granted, value

22,222

Frequency of vesting installments

Quarterly

Beginning date of shares vesting

1-Apr-14

Stock outstanding

30,000

30,000

30,000

Chief Executive Officer [Member]

Equity Issuance [Line Items]

Expiration period

10 years

Option granted, number of shares vesting in installments

10,000

Stock option expense

29,550

Option granted, shares (upper limit)

40,000

Option granted, purchase price

$0.92

Option granted, value

29,630

Frequency of vesting installments

Quarterly

Beginning date of shares vesting

1-Apr-14

Stock outstanding

40,000

40,000

40,000

Warrant Transaction for Consulting Services [Member]

Equity Issuance [Line Items]

Expiration period

5 years

Option granted, number of shares vesting in installments

7,500

Shares rescinded/forfeited

22,500

Stock option expense

39,061

Vesting immediately

25,000

Exercise price of warrants

$0.92

Fair value of warrant

66,936

Frequency of vesting installments

Monthly

Beginning date of shares vesting

1-Apr-14

Number of common shares that can be purchased through warrant

100,000

Stock outstanding

77,500

77,500

77,500

Option granted, total number of shares vesting in installments

75,000

New Director [Member]

Equity Issuance [Line Items]

Expiration period

10 years

Option granted, number of shares vesting in installments

50,000

Stock option expense

50,264

Vesting immediately

50,000

Option granted, shares (upper limit)

200,000

Option granted, purchase price

$0.76

Option granted, value

122,515

Frequency of vesting installments

Annually

Stock outstanding

200,000

200,000

200,000

New Director One [Member]

Equity Issuance [Line Items]

Expiration period

5 years

Option granted, number of shares vesting in installments

162,500

Stock option expense

580,167

306,765

Vesting immediately

162,500

Exercise price of warrants

$1.51

Fair value of warrant

1,188,000

Shares Expired

-487,500

Vesting period

3 years

Number of common shares that can be purchased through warrant

650,000

New Director One [Member] | Subsequent Event [Member]

Equity Issuance [Line Items]

Shares Expired

-487,500

Common Stock and Warrants [Member]

Equity Issuance [Line Items]

Expiration period

5 years

5 years

Proceeds from issuance of common stock and warrants

3,140,000

Number of units offered (upper limit)

60

Price per unit

50,000

Share issued, shares

4,207,600

Number of common shares that can be purchased through warrant

4,207,600

4,207,600

Common Stock and Warrants [Member] | Warrant One [Member]

Equity Issuance [Line Items]

Exercise price of warrants

$1

$1

$1

Number of common shares that can be purchased through warrant

2,103,800

2,103,800

2,103,800

Common Stock and Warrants [Member] | Warrant Two [Member]

Equity Issuance [Line Items]

Exercise price of warrants

$1.25

$1.25

$1.25

Number of common shares that can be purchased through warrant

2,103,800

2,103,800

2,103,800

Director Serving on Operations Committee [Member]

Equity Issuance [Line Items]

Stock option expense

14,000

Share issued, shares

2,408

2,081

2,371

2,487

2,322

2,121

1,897

Share issued, value

2,000

2,000

2,000

2,000

2,000

2,000

2,000

Director Serving on Operations Committee [Member] | Subsequent Event [Member]

Equity Issuance [Line Items]

Share issued, shares

2,576

2,524

Share issued, value

4,000

Common stock for investor relations services [Member]

Equity Issuance [Line Items]

Number of common stock issued for investor relations services

6,250

6,250

Fair value of common stock issued for investor relations services

5,063

5,437

Investor relations expense

10,500

Common stock for investor relations services [Member] | Subsequent Event [Member]

Equity Issuance [Line Items]

Number of common stock issued for investor relations services

6,250

6,250

6,250

Fair value of common stock issued for investor relations services

4,938

5,056

$5,250

STOCK_BASED_COMPENSATION_Narra

STOCK BASED COMPENSATION (Narrative) (Details) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected dividend yield
Expected volatility, minimum	70.25%	107.00%
Expected volatility, maximum	109.00%	113.00%
Risk-free interest rate, minimum	0.58%	0.94%
Risk-free interest rate, maximum	2.08%	1.86%
Unrecognized compensation expense related to non-vested market-based share awards	$324,004
Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected option life	2 years 1 month 17 days	3 years
Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected option life	7 years 3 months	10 years
Non-Qualified Stock Options and Warrants [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Aggregate intrinsic value of options and warrants outstanding and exercisable	92,950
Closing stock price of common stock	$0.77
Intrinsic value of options and warrants exercised	$232,139	32,139

STOCK_BASED_COMPENSATION_Sched

STOCK BASED COMPENSATION (Schedule of Stock Option and Warrant Outstanding and Exercisable)(Details) (Non-Qualified Stock Options and Warrants [Member], USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Non-Qualified Stock Options and Warrants [Member]
Number of Shares
Outstanding	7,146,000	8,773,500
Granted	5,257,600	560,000
Expired	-10,000	-1,971,650
Forfeited	-125,000	-120,000
Exercised	-449,000	-95,850
Outstanding	11,819,600	7,146,000	8,773,500
Exercisable	11,267,723
Exercise Price
Outstanding (Lower Limit)	$0.63	$0.25	$0.25
Outstanding (Upper Limit)	$1.75	$1.75	$1.75
Granted (Lower Limit)	$0.72	$0.84
Granted (Upper Limit)	$1.25	$1.16
Expired (Lower Limit)		$0.73
Expired	$1.25
Expired (Upper Limit)		$1.25
Forfeited (Lower Limit)	$0.92	$0.93
Forfeited (Upper Limit)	$1.03	$1.03
Exercised (Lower Limit)	$0.25	$0.35
Exercised (Upper Limit)	$0.35	$1.25
Outstanding (Lower Limit)	$0.63	$0.25	$0.25
Outstanding (Upper Limit)	$1.75	$1.75	$1.75
Exercisable (Lower Limit)	$0.63
Exercisable (Upper Limit)	$1.75
Weighted Average Exercise Price
Outstanding	$1.16	$1.13
Granted	$1.07	$0.96
Expired	$1.25	$1.02
Forfeited	$0.93	$0.99
Exercised	$0.34	$0.76
Outstanding	$1.15	$1.16	$1.13
Exercisable	$1.16

STOCK_BASED_COMPENSATION_Summa

STOCK BASED COMPENSATION (Summary of Stock Option and Warrant Outstanding) (Details) (Non Qualified Stock Options And Warrants [Member], USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Exercise Prices (Lower Limit)	$0.63	$0.25	$0.25
Exercise Prices (Upper Limit)	$1.75	$1.75	$1.75
$0.63 - $1.75 [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Exercise Prices (Lower Limit)	$0.63
Exercise Prices (Upper Limit)	$1.75
Number Outstanding Currently Exercisable	11,267,723
Weighted Average Remaining Contractual Life	3 years 6 months 29 days
Exercise Price	$1.16

RELATED_PARTY_Details

RELATED PARTY (Details) (USD $)	Dec. 31, 2014	Dec. 31, 2013
Officer [Member]
Related Party Transaction [Line Items]
Travel and office expense accruals	$1,144	$1,229
Two Beneficial Owners [Member]
Related Party Transaction [Line Items]
Accrued salaries		42,088
Related Party [Member]
Related Party Transaction [Line Items]
Legal accrual	$8,258	$5,500

SUBSEQUENT_EVENTS_Details

SUBSEQUENT EVENTS (Details) (USD $)	1 Months Ended	12 Months Ended		1 Months Ended	0 Months Ended
	Jan. 31, 2010	Dec. 31, 2011	Dec. 31, 2010	Mar. 31, 2015	Jan. 02, 2015	Jan. 01, 2015
New member of board of directors [Member]
Subsequent Event [Line Items]
Number of common shares that can be purchased through warrant	650,000
Exercise price of warrants	$1.51
Fair value of warrant	$1,188,000
Expiration period	5 years
Vesting immediately	162,500
Option granted, number of shares vesting in installments	162,500
Vesting period	3 years
Stock option expense		306,765	580,167
Shares Expired		-487,500
Subsequent Event [Member]
Subsequent Event [Line Items]
Annual lease expenses				71,662
Subsequent Event [Member] | Senior Advisor Two [Member]
Subsequent Event [Line Items]
Number of common shares that can be purchased through warrant						100,000
Exercise price of warrants						$0.77
Fair value of warrant						48,656
Expiration period					5 years
Vesting immediately					25,000
Option granted, number of shares vesting in installments					7,500
Vesting period					10 months
Subsequent Event [Member] | Employee [Member]
Subsequent Event [Line Items]
Expiration period				10 years	10 years
Vesting immediately					7,500
Option granted, number of shares vesting in installments					7,500
Vesting period					3 months
Option granted, shares (upper limit)				2,500	15,000
Option granted, purchase price				$0.80	$0.77
Option granted, value				1,231	7,362
Subsequent Event [Member] | New member of board of directors [Member]
Subsequent Event [Line Items]
Shares Expired					-487,500
Subsequent Event [Member] | Independent Directors [Member]
Subsequent Event [Line Items]
Expiration period				10 years
Vesting immediately				20,000
Option granted, number of shares vesting in installments				10,000
Number of person to whom option were granted				5
Option granted, shares (upper limit)				50,000
Option granted, purchase price				$0.80
Option granted, value				$24,901